Shuttle Pharmaceuticals Inc (SHPH) - Total Assets
Based on the latest financial reports, Shuttle Pharmaceuticals Inc (SHPH) holds total assets worth $10.48 Million USD as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See SHPH net assets for net asset value and shareholders' equity analysis.
Shuttle Pharmaceuticals Inc - Total Assets Trend (2017–2025)
This chart illustrates how Shuttle Pharmaceuticals Inc's total assets have evolved over time, based on quarterly financial data.
Shuttle Pharmaceuticals Inc - Asset Composition Analysis
Current Asset Composition (December 2025)
Shuttle Pharmaceuticals Inc's total assets of $10.48 Million consist of 4.8% current assets and 95.2% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 3.2% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $9.84 Million | 93.9% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2017–2025)
This chart illustrates how Shuttle Pharmaceuticals Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Shuttle Pharmaceuticals Inc stock valuation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Shuttle Pharmaceuticals Inc's current assets represent 4.8% of total assets in 2025, a decrease from 84.5% in 2017.
- Cash Position: Cash and equivalents constituted 3.2% of total assets in 2025, down from 41.8% in 2017.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 93.0% of total assets, an increase from 0.0% in 2017.
- Asset Diversification: The largest asset category is intangible assets at 93.9% of total assets.
Shuttle Pharmaceuticals Inc Competitors by Total Assets
Key competitors of Shuttle Pharmaceuticals Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Changchun High & New Technology Industries Group Inc
SHE:000661
|
China | CN¥31.46 Billion |
|
Yuhan Corp.
KO:000100
|
Korea | ₩3.05 Trillion |
|
Tasly Pharmaceutical Group Co Ltd
SHG:600535
|
China | CN¥15.34 Billion |
|
Zhejiang Hisun Pharmaceutical Co Ltd
SHG:600267
|
China | CN¥15.32 Billion |
|
Zhejiang Jiuzhou Pharm Co Ltd
SHG:603456
|
China | CN¥10.96 Billion |
|
Shanghai Yizhong Pharmaceutical Co Ltd
SHG:688091
|
China | CN¥1.54 Billion |
|
Jiangsu Kanion Pharmaceutical Co Ltd
SHG:600557
|
China | CN¥6.74 Billion |
|
Cronos Group Inc
TO:CRON
|
Canada | CA$1.18 Billion |
Shuttle Pharmaceuticals Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.06 | 1.44 | 0.23 |
| Quick Ratio | 0.06 | 1.44 | 0.23 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $-7.46 Million | $677.15K | $-1.71 Million |
Shuttle Pharmaceuticals Inc - Advanced Valuation Insights
This section examines the relationship between Shuttle Pharmaceuticals Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.88 |
| Latest Market Cap to Assets Ratio | 0.37 |
| Asset Growth Rate (YoY) | 318.0% |
| Total Assets | $10.48 Million |
| Market Capitalization | $3.87 Million USD |
Valuation Analysis
Below Book Valuation: The market values Shuttle Pharmaceuticals Inc's assets below their book value (0.37x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Shuttle Pharmaceuticals Inc's assets grew by 318.0% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Shuttle Pharmaceuticals Inc (2017–2025)
The table below shows the annual total assets of Shuttle Pharmaceuticals Inc from 2017 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $10.48 Million | +317.99% |
| 2024-12-31 | $2.51 Million | -57.89% |
| 2023-12-31 | $5.95 Million | -31.22% |
| 2022-12-31 | $8.65 Million | +1227.96% |
| 2021-12-31 | $651.64K | +19.78% |
| 2020-12-31 | $544.05K | -12.43% |
| 2018-12-31 | $621.27K | +412.19% |
| 2017-12-31 | $121.30K | -- |
About Shuttle Pharmaceuticals Inc
Shuttle Pharmaceuticals Holdings, Inc., a clinical stage pharmaceutical company, develops novel therapies to cure cancers. The company is developing Ropidoxuridine, an oral halogenated pyrimidine to treat patients with brain tumors and sarcomas; and SP-2-225, a pre-clinical class IIb product candidate that effects on the regulation of the immune system. It is also developing SP-1-303, a pre-clini… Read more